Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Post by adamchesson Nov 26, 2015 2:11am
155 Views
Post# 24327071

EPS for 2016?

EPS for 2016?

 

Does anyone know this number? From the information below I could conclude it is $7.00

for example, nine months 2015, EBITDA of 146.8 million resulted in EPS of $3.14 and 2016 EBITDA of 640 million is more than 4 times 2015 9 months amount. thus 4 x $3.14 = $12.56

This would be lowered by higher interest cost of $5/sh and 25% more shares, so 2016 EPS is probably between $6 to $8. Where does that put CXR valuation? $140?? using multiple of 20 times

Home Depot trades at $135 US on expected 2015 EPS $5.36. A multiple of 25 times. CXR expected growth 2017 will dwarf HD percentage wise.


- A transformational quarter with strong performance by legacy business -

Third Quarter 2015 Highlights

  • Concordia announced its acquisition of Amdipharm Mercury Limited ("AMCo") for $3.3 billion 1.
  • Adjusted EBITDA2 of $71.7 million , growing 254 per cent versus the same period in 2014.
  • Adjusted EPSof $1.46 , growing 157 per cent over the third quarter in 2014.
  • Revenue growth of 161 per cent to $94.9 million compared to the third quarter of 2014.

 

2015 Nine Month Highlights

  • Revenue growth of 163 per cent to $208.9 million compared to the same period in 2014.
  • Adjusted EBITDA2 of $146.8 million , growing 280 per cent versus the same period in 2014.
  • Adjusted EPS2 of $3.14 a growth of 185 per cent versus the first nine months of 2014.

 

2016 Guidance Reaffirmed

  • Adjusted EBITDA2 of $610 million to $640 million .
<< Previous
Bullboard Posts
Next >>